E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045365 |
E.1.2 | Term | Ulcerative colitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
INDUCTION THERAPY
Demonstrate the efficacy of RPC1063 versus placebo on induction of clinical remission in adults.
MAINTENANCE THERAPY
To demonstrate the efficacy of RPC1063 versus placebo maintenance therapy on clinical remission in adults. |
|
E.2.2 | Secondary objectives of the trial |
INDUCTION THERAPY
Demonstrate the efficacy of RPC1063 versus placebo
- on induction of clinical response in adults.
- on achieving endoscopic improvement in adults.
- on achieving histologic remission in adults.
Demonstrate the safety and tolerability of RPC1063 induction therapy in
all patients.
MAINTENANCE THERAPY
Demonstrate the efficacy of RPC1063 versus placebo
- in maintaining clinical response in adults.
- on achieving endoscopic improvement in adults.
- on durability of clinical remission in adults.
- on maintaining clinical remission among patients who achieved
remission during induction therapy in adults.
- in achieving corticosteroid-free remission among patients receiving
corticosteroids at entry into the Maintenance Period in adults.
Demonstrate the safety and tolerability of RPC1063 maintenance therapy
in all patients. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Must meet one of the following criteria:
- Male or female adult patients aged 18 to 75 years (at Screening),
Cohort 1 or Cohort 2, or
- Male or female adolescent patients aged 12 to < 18 years (at
Screening) with a body weight ≥ 45 kg for Cohort 3.
Note: Countries or sites with local restrictions that prohibit enrollment of
adolescents (aged 12 to<18 years) will only enroll patients who are
aged 18 to 75 years, inclusive. Enrollment of adolescent patients will
only begin after the applicable regulatory requirements for studying
patients in that age group have been satisfied and the necessary health
authority agreements have been granted.
2. Have had UC diagnosed at least 3 months prior to first investigational
drug administration. The diagnosis should be confirmed by clinical and
endoscopic evidence and corroborated by a histopathology report (note:
endoscopy and histopathology may be performed at Screening if no prior
report is readily available)
3. Evidence of UC extending ≥ 15 cm from the anal verge as determined
by Baseline endoscopy (flexible sigmoidoscopy or colonoscopy)
4. Have active UC defined as a complete Mayo score of 6 to 12 inclusive,
with endoscopic subscore of ≥ 2, a rectal bleeding score of ≥ 1, and a
stool frequency score ≥ 1
5. Must be currently receiving treatment with at least 1 of the following
therapies and must continue on these therapies during Induction:
- Oral aminosalicylates at a therapeutic dose for their disease (eg,
mesalamine, sulfasalazine, olsalazine, balsalazide), with the dose stable
for at least 3 weeks, prior to Screening endoscopy
- Prednisone (doses ≤ 20 mg per day) or equivalent receiving a stable
dose for at least 2 weeks prior to Screening endoscopy
- Budesonide MMX therapy receiving a stable dose for at least 2 weeks
prior to Screening endoscopy
6. Have undergone colonoscopy (or are willing to undergo colonoscopy
during Screening):
- within the past 2 years, to screen for dysplasia (unless otherwise
recommended by local and national guidelines) if the patient has had
left-sided colitis of > 12 years duration or total/extensive colitis of > 8
years duration
- within the past 5 years, to screen for polyps if the patient age is > 45
years
- If oral aminosalicylates or corticosteroids have been recently
discontinued, they must have been stopped for at least 2 weeks prior to
the endoscopy used for Baseline Mayo score
7. Females of childbearing potential (FCBP): Must agree to practice a
highly effective method of contraception throughout the trial until
completion of the 90-day Safety Follow-up Visit. Highly effective
methods of contraception are those that alone or in combination result in
a failure rate of a Pearl index of less than 1% per year when used
consistently and correctly. Acceptable methods of birth control in the
trial are the following:
combined hormonal (oestrogen and progestogen containing)
contraception, which may be oral, intravaginal, or transdermal
progestogen-only hormonal contraception associated with inhibition of
ovulation, which may be oral, injectable, or implantable
placement of an intrauterine device (IUD)
placement of an intrauterine hormone-releasing system (IUS)
bilateral tubal occlusion
vasectomized partner
complete sexual abstinence
Periodic abstinence (calendar, symptothermal, post-ovulation methods),
withdrawal (coitus interruptus), spermicides only, and lactational
amenorrhoea method are not acceptable methods of contraception.
8. Must provide written informed consent/assent and have the ability to
parent/legal guardian of the adolescent must sign an informed consent
form. In addition, adolescent patients must also agree to participate in
the study by signing an assent.
9. Patients must have documentation of positive Varicella zoster virus
(VZV) immunoglobulin G (IgG) antibody status or complete VZV
vaccination at least 30 days prior to randomization |
|
E.4 | Principal exclusion criteria |
1. Have severe extensive colitis as evidenced by:
• Physician judgment that the patient is likely to require colectomy or
ileostomy within 12 weeks of Baseline • Current or recent (within 3
months) evidence of fulminant colitis, toxic megacolon, or bowel
perforation
2. Diagnosis of Crohn's disease or indeterminate colitis or the presence
or history of a fistula consistent with Crohn's disease or microscopic
colitis or radiation colitis or ischemic colitis
3. Have positive stool examination for pathogens (ova and parasites,
bacteria) or positive test for toxin producing Clostridium difficile (C.
difficile) at Screening. PCR (polymerase chain reaction) examination of
the stool for C. difficile may be used to exclude false positives. If
positive, patients may be treated and retested. Documentation of a
negative test result for pathogens (ova and parasites, bacteria) is
required within 60 days of Day 1
4. Pregnancy, lactation, or a positive serum β-human chorionic
gonadotropin (β-hCG) measured during Screening
5. Clinically relevant hepatic, neurological, pulmonary, ophthalmological,
endocrine, psychiatric, or other major systemic disease making
implementation of the protocol or interpretation of the trial difficult or
that would put the patient at risk by participating in the trial
6. Clinically relevant cardiovascular conditions, including history or
presence of:
• Recent (within the last 6 months) occurrence of myocardial infarction,
unstable angina, stroke, transient ischemic attack, decompensated heart
failure requiring hospitalization, Class III/IV heart failure, sick sinus
syndrome, or severe untreated sleep apnea
• For Adult patients: Prolonged Fridericia's corrected QT interval (QTcF;
QTcF > 450 msec for males, > 470 msec for females), or at additional
risk for QT interval prolongation
• For Adolescent patients: Prolonged Fridericia's corrected QT interval
(QTcF; QTcF >450 msec for both males and females), or at additional
risk for QT interval prolongation
• Resting HR <55 bpm when taking vital signs as part of a physical exam
at Screening
7. History of diabetes mellitus type 1, or uncontrolled diabetes mellitus
type 2 with glycosylated Hb (HbA1c) > 9%, or diabetic patients with
significant comorbid conditions such as retinopathy or nephropathy
8. History of uveitis (within the last year) or macular edema
9. Subject has a known active bacterial, viral, or fungal infection
[excluding fungal infection of nail beds, minor upper respiratory tract
infections, and minor skin infections] a mycobacterial infection
(including tuberculosis[TB] or atypical mycobacterial disease),or any
major episode of infection that required hospitalization or treatment
with intravenous (IV) antibiotics within 30 days of Screening or oral
antibiotics within 14 days of Screening
10. History of cancer, including solid tumors and hematological
malignancies (except basal cell and in situ squamous cell carcinomas of
the skin or uterine cervix that have been excised and resolved) or
colonic mucosal dysplasia
12. History of treatment with a biologic agent within 8 weeks or 5
elimination half-lives (whichever is less) of that agent prior to
randomization
13. History of treatment with an investigational agent within 5
elimination half-lives of that agent prior to randomization
14. History of treatment with topical rectal 5-aminosalicylic acid or
topical rectal steroids within 2 weeks of Screening endoscopy or antimotility
medications during Screening
15. Receipt of a live vaccine or live attenuated vaccine within 4 weeks
prior to randomization
16. Planned concurrent treatment with immunosuppressive agents (eg,
azathioprine [AZA], 6-mercaptopurine [6-MP], or methotrexate) after
randomization. Patients receiving AZA, 6-MP, or methotrexate at
Screening must discontinue treatment with these agents prior to
randomization
17. Treatment with Class Ia or Class III anti-arrhythmic drugs or
treatment with two or more agents in combination known to prolong PR
interval
18. Patients who were primary non-responders to 2 or more biologic
agents approved for the treatment of UC (eg anti-TNF agents or
vedolizumab)
19. Serum creatinine > 1.4 mg/dL for females or > 1.6 mg/dL for males
20. Liver function impairment or persisting elevations of aspartate
aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the
upper limit of normal (ULN), or direct bilirubin > 1.5 times the ULN
26. ECG showing any clinically significant abnormality
27. Forced expiratory volume at 1 second (FEV1) or forced vital capacity
(FVC) < 70% of predicted values at screening
28. Patient receiving treatment with breast cancer resistance protein
(BCRP) inhibitors (eg cyclosporine, eltrombopag)
30. Adolescent patients with delayed growth or delayed pubertal
development and who will not maintain a stable dose of corticosteroids
through Week 10.
31-39 Abnormal lab results |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The efficacy endpoints will be formally examined with statistical
hypothesis tests conducted on the efficacy results obtained from adult
patients randomized and dosed in Cohort 1. Cohort 2 is open-label and
does not contain a control group,therefore all of the efficacy endpoints
will be summarized and described without statistical hypothesis testing.
The analysis of adolescent patients (aged 12 up to < 18 years; Cohort 3)
will be performed independently from the analysis of adult patients.
Efficacy results in the Induction Period will be evaluated for similar
efficacy trends between Cohort 1 and Cohort 3. No formal hypothesis
testing is planned for Cohort 3 data.
INDUCTION PERIOD Cohort 1
- The proportion of adult patients in clinical remission at Week 10.
INDUCTION PERIOD Cohort 2
Cohort 2 is open label; therefore no formal analysis of efficacy endpoints
will be conducted.
All efficacy endpoints will be summarized and described without
hypothesis testing and reported using descriptive statistics.
MAINTENANCE PHASE Cohort 1 and Cohort 2 in Adult Patients
Primary Efficacy Endpoint:
- The proportion of adult patients in clinical remission at 52 weeks |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At 10 weeks (Induction Visit I4/Week 10)
At 52 weeks (Maintenance Visit M5/Week 42)
|
|
E.5.2 | Secondary end point(s) |
INDUCTION PERIOD Cohort 1
- The proportion of adult patients with a clinical response at Week 10
- The proportion of adult patients with endoscopic improvement at Week
10
- The proportion of adult patients with mucosal healing at Week 10
MAINTENANCE PHASE
Key Secondary Efficacy Endpoints:
- The proportion of adult patients with a clinical response at 52 weeks
- The proportion of adult patients with endoscopic improvement at 52
weeks
- The proportion of adult patients with durable clinical remission
- The proportion of adult patients in clinical remission at 52 weeks in the
subset of patients who were
in remission at Week 10
- The proportion of adult patients with corticosteroid-free remission
- The proportion of adult patients with mucosal healing at 52 weeks
OTHER ENDPOINTS
Safety
Pharmacokinetic and pharmacodynamic |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At 10 weeks (Induction Visit I4/Week 10)
At 52 weeks (Maintenance Visit M5/Week 42)
From the list of Other efficacy endpoints during maintenance phase (not
primary or secondary) some endpoints are evaluated at 28 weeks (Maintenance Visit M3/Week 18), 40 weeks (Maintenance Visit M3/Week 30) and 52 weeks (Maintenance Visit M3/Week 42). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Induction (Coh1 & 3: Random PlaceboContr; Coh2: OpenLabel; ); Maintenance (PlaceboContr) |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 117 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Belarus |
Belgium |
Bulgaria |
Canada |
Croatia |
Czech Republic |
Georgia |
Germany |
Greece |
Hungary |
Israel |
Italy |
Korea, Republic of |
Latvia |
Moldova, Republic of |
Netherlands |
New Zealand |
Poland |
Romania |
Russian Federation |
Serbia |
Slovakia |
South Africa |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |